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ABSTRACT		
	
The	idea	that	chemotherapy	can	be	used	in	combination	with	immunotherapy	may	
seem	somewhat	counterproductive,	since	it	can	theoretically	eliminate	the	immune	
cells	 needed	 for	 anti-tumour	 immunity.	 However,	much	 pre-clinical	work	 has	 now	
demonstrated	 that	 in	 addition	 to	 direct	 cytotoxic	 effects	 on	 cancer	 cells,	 a	
proportion	of	DNA	damaging	agents	may	actually	promote	immunogenic	cell	death,	
alter	 the	 inflammatory	 milieu	 of	 the	 tumour	 microenvironment	 and/or	 stimulate	
neo-antigen	production,	thereby	activating	an	anti-tumour	immune	response.	Some	
notable	combinations	have	now	moved	forward	into	the	clinic,	showing	promise	 in	
Phase	I-III	trials,	while	others	have	proven	toxic,	and	challenging	to	deliver.		
	
In	 this	 review,	 we	 discuss	 the	 emerging	 data	 of	 how	 DNA	 damaging	 agents	 can	
enhance	 the	 immunogenic	 properties	 of	 malignant	 cells,	 focusing	 especially	 on	
immunogenic	cell	death,	and	the	expansion	of	neo-antigen	repertoires.	We	discuss	
how	best	to	strategically	combine	DNA	damaging	therapeutics	with	immunotherapy,	
and	 the	 challenges	 of	 successfully	 delivering	 these	 combination	 regimens	 to	
patients.	 With	 an	 overwhelming	 number	 of	 chemotherapy/immunotherapy	
combination	trials	in	process,	clear	hypothesis-driven	trials	are	needed	to	refine	the	
choice	of	combinations,	and	determine	the	timing	and	sequencing	of	agents	in	order	
to	 stimulate	 anti-tumour	 immunological	memory	 and	 improve	maintained	 durable	
response	rates,	with	minimal	toxicity.		
	
Keywords:	 DNA	 damage,	 chemotherapy,	 immunotherapy,	 immune	 checkpoint	
inhibitors,	 PD-1,	 PD-L1,	 CTLA-4,	 immunogenic	 cell	 death,	 neoantigens,	 mutational	
load.	
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Introduction		
	
Without	 doubt,	 a	 subset	 of	 cancer	 patients	 have	 experienced	 tremendous	 benefit	
from	 the	 clinical	 implementation	 of	 immune	 checkpoint	 inhibitors	 and	 naturally	
therefore,	 attention	 is	 now	 focusing	 on	 mechanisms	 by	 which	 primary	 and	
secondary	 resistance	 can	 be	 overcome.	 This	 has	 largely	 been	 approached	 though	
therapeutic	 combination	 strategies	 and	 the	 recent	 publication	 of	 Keynote	 021	
(Langer	et	al,	2016),	demonstrates	that	such	combinations	are	safe	and	can	be	more	
effective	than	chemotherapy	alone.	Keynote	021	is	the	first	trial	to	publish	a	benefit	
of	 immune-checkpoint	 inhibition	 with	 a	 PD1	 inhibitor	 in	 combination	 with	
chemotherapy	 over	 chemotherapy	 alone,	 in	 this	 case	 as	 first	 line	 treatment	 for	
patients	 with	 non-small	 cell	 lung	 cancer	 (NSCLC).	 Whether	 this	 represents	 a	
synergistic	 interaction	 between	 chemotherapy	 and	 immune	 checkpoint	 inhibition	
rather	 than	an	additive	effect	has	 yet	 to	be	established,	however,	 there	 is	 a	 great	
deal	 of	 evidence	 in	 support	 of	 combining	 DNA	 damaging	 agents	 with	 immune	
modulating	drugs.	
	
In	 this	 review	 we	 will	 discuss	 the	 pre-clinical	 rationale	 for	 combining	 immune-
checkpoint	 inhibitors	 with	 DNA	 damaging	 agents.	 We	 will	 summarise	 the	 clinical	
experience	with	such	combinations	 so	 far	and	highlight	 the	challenges	 faced	when	
combining	immunotherapy	with	DNA	damaging	therapeutics	in	the	clinic.	
Tumour	Immunosurveillance	
	
The	host	 immune	 system	actively	protects	 itself	 against	 tumour	development,	 and	
evasion	of	cancer	immunosurveillance	through	both	local	immunosuppression	within	
the	 tumour	 microenvironment	 (TME)	 and	 emergence	 of	 an	 immunoevasive	
phenotype	through	 immunoediting	 is	an	emerging	hallmark	of	many	solid	 tumours	
(Schreiber	et	al,	2011;	Joyce	&	Fearon,	2015).		
	
The	 existence	 of	 tumour	 specific	 antigens,	 which	 may	 include	 the	 products	 of	
mutated	genes	(neo-antigens),	or	proteins	expressed	only	in	the	tumour	and	not	in	
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normal	tissues	for	example,	has	been	known	for	some	time	(Schreiber	et	al,	2011).	
Immunoediting	 involves	 the	 elimination	 of	 immunologically	 foreign	 tumour	 cells	
through	 the	 activity	 of	 the	 innate	 and	 adaptive	 immune	 systems	 (Schreiber	 et	 al,	
2011).	 This	 may	 serve	 to	 eradicate	 the	 tumour	 entirely,	 or	 as	 a	 result	 of	 tumour	
heterogeneity,	selectively	destroy	highly	immunogenic	tumour	cells,	which	over	time	
results	 in	 a	 tumour	 largely	 composed	 of	 poorly	 immunogenic	 and	 immunoevasive	
cells	(Schreiber	et	al,	2011).		
	
An	 effective	 adaptive	 immune	 response	 requires	 that:	 cytotoxic	 T	 cells	 (CD8+)	 are	
sufficiently	 activated,	 that	 tumour	 specific	 T	 cells	 navigate	 to	 the	 tumour;	
extravasate	 from	 the	 vasculature	 and	 cross	 the	 TME,	 before	 recognising	 and	
responding	to	their	target	antigen.	The	mere	presence	of	tumour	specific	cytotoxic	T	
cells	 therefore,	 is	 not	 sufficient	 for	 immune-mediated	 tumour	 cell	 death	 and	
extrinsic	 to	 the	 tumour	 cells	 themselves,	 early	 adoption	of	 an	 immunosuppressive	
TME	 enables	 tumours	 to	 develop	 in	 what	 are	 essentially	 immune-privileged	 sites	
(Joyce	 &	 Fearon,	 2015).	 This	 immunosuppression	 is	 essential	 in	 evading	
immunosurveillance	and	 is	achieved	through	a	number	of	overlapping	mechanisms	
(Box	1).	
Immune	checkpoint	inhibitors	
	
Most	recently,	clinical	focus	has	centred	on	the	T	cell	immune	checkpoint	inhibitors.	
T-cell	activation	requires	the	interaction	between	the	T	cell	receptor	(TCR)	and	major	
histocompatability	complex	(MHC)	bound	to	tumour	derived	peptide	on	the	antigen	
presenting	cell	(APC),	alongside	costimulation	provided	by	interaction	between	CD28	
on	the	T	cell	and	B7	ligand	on	the	APC	(Sharma	&	Allison,	2015).		Immune	checkpoint	
inhibitors	release	the	physiological	suppression	of	T	cell	activation.		
	
CTLA-4	 is	 a	 T	 cell	 inhibitory	 receptor	 that	 competitively	 antagonises	 the	 co-
stimulatory	interaction	between	CD28	and	B7	ligand.	Expression	of	CTLA-4	on	T	cells	
is	induced	following	T	cell	activation	where	it	functions	to	attenuate	and	eventually	
terminate	 T	 cell	 activation	 (Sharma	 &	 Allison,	 2015).	 Anti-CTLA-4	 monoclonal	
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antibody	 (mAb)	 treatment	 therefore	 results	 in	 persistent	 T	 cell	 activation	 and	
subsequent	 trafficking	of	T	 cells	 to	 sources	of	antigen.	 Its	use	has	been	associated	
with	 an	 increased	 number	 of	 new	 tumour-specific	 CD8+	 T	 cells	 in	 patients	 with	
melanoma,	 suggesting	 that	 it	 broadens	 the	 immune	 response,	 rather	 than	 just	
stimulating	it	(Kvistborg	et	al,	2014).		It	has	also	been	shown	to	deplete	regulatory	T	
(Treg)	cells	 in	the	tumour	microenvironment	(Simpson	et	al,	2013).	Ipilumumab,	an	
antibody	 against	 human	 CTLA-4	 was	 licensed	 in	 2011	 after	 showing	 significant	
clinical	benefit	in	patients	with	metastatic	melanoma	(Hodi	et	al,	2010)	(Table	1).		
	
The	second	class	of	immune	checkpoint	inhibitors	that	are	transforming	standard	of	
care	 across	 a	 range	 of	 tumour	 types,	 are	 inhibitors	 of	 programmed	 cell	 death-
1/programmed	cell	death	ligand-1	(PD-1/PD-L1)	signalling.	Similarly	to	CTLA-4,	PD-1	
is	expressed	on	activated	T	cells,	however,	unlike	CTLA-4,	PD-1	 interaction	with	 its	
most	studied	ligands	PD-L1	or	PD-L2	inhibits	T	cell	activation	through	interfering	with	
downstream	TCR	signalling	(Patsoukis	et	al,	2012).	IFN-γ,	released	as	a	result	of	T	cell	
activation,	 can	 induce	 PD-L1	 expression	 on	 a	 range	 of	 cell	 types,	 including	 non-
lymphoid	tissue	such	as	epithelial,	endothelial	and	tumour	cells,	(Sharma	&	Allison,	
2015).	PD-L1	expression	in	tumours	is	therefore	driven	by	the	presence	of	activated	
T	 cells	 in	 the	 TME	 and	 upregulation	 of	 PD-L1	 in	 tumours	 is	 an	 effective	means	 of	
evasion	 of	 immunosurveillance.	 PD-L2	 expression,	 whilst	 also	 being	 cytokine	
induced,	is	restricted	to	macrophages	and	dentritic	cells	(Greenwald	et	al,	2005).		
	
Current	thinking	is	that	CTLA-4	is	required	for	limiting	T	cell	activity	centrally	within	
the	 lymphovascular	 system	 (central	 immune	 tolerance),	 whereas	 PD-1	 signalling	
plays	 a	 more	 prominent	 role	 during	 later	 stages	 of	 the	 immune	 response	 and	 is	
required	 for	 the	 inhibition	 of	 T	 cell	 signalling	 in	 peripheral	 tissues	 (peripheral	
tolerance).	 Pembrolizumab	 and	 nivolumab;	 both	 PD-1	 inhibitors,	 as	 well	 as	
atezolizumab	and	durvalumab;	a	PD-L1	inhibitor,	all	now	hold	licenses	for	clinical	use	
(Table	1).	
Effects	of	DNA	damaging	agents	on	the	immune	system	
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DNA	 damage	 arises	 either	 due	 to	 cellular	 exposure	 to	 exogenous	 sources	 of	
damaging	 agents	 such	 as	 chemotherapy,	 or	 because	 of	 a	 failure	 to	 repair	
endogenous	DNA	damage	 in	cells	 (Jackson	&	Bartek,	2009).	DNA	damage	 itself	can	
take	many	different	forms	depending	on	the	mechanism	of	action	of	the	agent	used	
(Box	2),	with	DNA	double	strand	breaks	(DSBs)	considered	to	be	the	most	cytotoxic	
to	 cancer	 cells	 (Brown	 et	 al,	 2017).	 DNA	 damaging	 agents	 are	 widely	 used	 as	
standard	of	care	treatment	across	a	range	of	tumour	types.	 Inhibiting	the	repair	of	
endogenous	or	exogenous	DNA	damage	is	also	an	attractive	anticancer	strategy	and	
several	 different	 DNA	 repair	 inhibitors	 are	 in	 clinical	 development	 (Brown	 et	 al,	
2017).	 Whilst	 in	 this	 review	 we	 will	 focus	 on	 the	 immunomodulatory	 effects	 of	
chemotherapy,	as	well	as	the	newer	DNA	repair	inhibitors,	it	must	be	noted	that	the	
immune	 effects	 of	 radiotherapy	 are	 also	 well-reported	 and	 have	 recently	 been	
reviewed	elsewhere	(Weichselbaum	et	al,	2017).		
	
Traditionally,	 chemotherapy	 has	 been	 considered	 immunosuppressive	 and	 several	
chemotherapeutics,	such	as	methotrexate	and	cyclophosphamide,	are	used	to	treat	
autoimmune	 conditions.	 The	 choice	 of	 DNA	 damaging-therapeutic	 agent,	 dose	 of	
compound	 and	 timing	 of	 these	 combinations	 is	 important	 therefore,	 not	 least	
because	 many	 cytotoxic	 chemotherapeutics	 have	 the	 potential	 to	 deplete	 rapidly	
dividing	 immune-cell	 populations.	DNA	damaging	agents	have	now	been	 shown	 to	
promote	 immunogenicity	 in	 a	 variety	 of	 ways	 however,	 many	 of	 which	 have	 the	
potential	to	be	exploited	in	a	clinical	setting	(Figure	1).		
	
1. Increasing	neoantigen	repertoire	
	
Tumour	neoantigens	are	predominantly	 felt	 to	be	the	consequences	of	the	genetic	
alterations	 accumulated	 by	 cancer	 cells	 during	 tumourigenesis.	 They	 have	 been	
demonstrated	 to	 arise	 from	 various	 processes	 that	 alter	 the	 open	 reading	 frame	
(ORF)	sequences	in	the	genome	(Hacohen	et	al,	2013).	Not	only	missense	mutations,	
but	 also	 fusion	 transcripts,	 frameshifts,	 and	 stop	 losses	 can	 also	potentially	 create	
altered	 ORFs	 (i.e.	 neoORFS)	 encoding	 novel	 stretches	 of	 amino	 acids	 that	 are	 not	
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present	in	the	normal	genome.	A	significant	advantage	of	increasing	neoantigen	load	
is	that	neoantigens	are	tumour-specific	and	central	T	cell	tolerance	is	therefore	not	a	
concern.	Neoantigens	are	however	patient-specific	and	stimulating	T	cell	responses	
against	 tumour-specific	 immunogenic	 clonal	 neoantigens	 is	 currently	 not	 a	 high	
throughput	strategy	
	
There	 is	 accumulating	 evidence	 to	 suggest	 that	 high	mutational	 load	equates	with	
increased	 antigenicity,	 however,	 as	 directly	 identifying	 HLA-bound	 neoantigens	 on	
tumour	 tissue	 has	 yet	 to	 be	 successful,	 proving	 this	 association	 definitively	 is	
difficult,	 and	 most	 studies	 rely	 on	 mathematical	 predictions	 of	 neoantigen	 load.	
Tumours	vary	in	the	number	of	somatic	mutations	they	harbor,	with	melanoma,	lung	
and	bladder	cancer	having	on	average	the	highest	mutational	load	(Alexandrov	et	al,	
2013)	and	also	showing	highest	responses	to	immune	checkpoint	 inhibitors.	Within	
tumour	types,	high	mutational	load	has	been	demonstrated	to	correlate	with	clinical	
benefit	to	PD-1	and	CTLA-4	 inhibitors	 in	NSCLC	and	melanoma	respectively	(Snyder	
et	al,	2014;	Rizvi	et	al,	2015).	Most	studies	 to	date	have	 focused	on	the	burden	of	
single	 nucleotide	 variants	 (SNVs)	 as	 a	 measure	 of	 mutational	 load,	 however	 the	
quantity	of	small	 insertions	and	deletions	(indels)	resulting	in	frameshift	mutations,	
also	 correlates	 with	 checkpoint	 inhibitor	 response	 in	 melanoma	 patient	 cohorts	
(Turajlic	 et	 al,	 2017)	 demonstrating	 that	 frameshift	 mutations	 are	 also	 likely	 to	
significantly	contribute	to	neoantigen	repertoire.	In	addition,	frameshift	mutations	in	
microsatellite	 unstable	 colorectal	 cancers	 have	 been	 shown	 to	 correlate	 with	 the	
density	of	CD8+	T-cell	infiltrate	in	tumours	(Maby	et	al,	2015).	
	
In	a	phase	II	study	of	pembrolizumab	in	colorectal	cancer,	response	rate	and	immune	
related	progression	free	survival	was	significantly	greater	in	tumours	with	mismatch	
repair	 deficiency	 status	 compared	 to	 those	 without	 (Le	 et	 al,	 2015).	 On	 average,	
1,782	somatic	mutations	were	 identified	 in	mismatch	repair-deficient	tumours	 (n	=	
9)	 (by	 far	 surpassing	 the	 mutational	 load	 in	 melanoma	 and	 NSCLC),	 whereas,	 on	
average,	 only	 73	 somatic	 mutations	 were	 observed	 in	 mismatch	 repair-proficient	
tumours	 (n	 =	 6)	 (Le	 et	 al,	 2015).	 This	 is	 predicted	 to	 translate	 into	 20x	 more	
mutation-associated	 neoantigens	 in	 mismatch	 repair	 deficient	 compared	 to	
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mismatch	proficient	tumours	(Le	et	al,	2015).	In	microsatellite	unstable	endometrial	
cancer	due	to	mutations	in	DNA	polymerase	epsilon	(POLE),	there	is	a	higher	number	
of	CD3+	and	CD8+	tumour	 infiltrating	 lymphocytes	(TILs),	as	well	as	 increased	PD-1	
expression	 on	 TILs	 compared	 to	 microsatellite	 stable	 tumours,	 possibly	 due	 to	
increased	 antigenicity	 (Howitt	 et	 al,	 2015).	 Similarly,	 in	 a	 case	 of	 hypermutated	
glioblastoma	(GBM)	associated	with	a	germline	mutation	 in	DNA	POLE,	 clinical	and	
immunological	 response	 to	 immune	checkpoint	 inhibition	with	pembrolizumab	has	
been	demonstrated	(Johanns	et	al,	2016).		
	
As	 well	 as	 studies	 demonstrating	 associations	 between	 mutational	 load	 and	
response	 to	 immune	 checkpoint	 inhibition,	 a	 recent	 study	 has	 demonstrated	 that	
loss	of	mutation-associated	neoantigens	in	tumours	is	associated	with	resistance	to	
immune	 checkpoint	 inhibitor	 treatment	 in	 patients	with	NSCLC	 (Anagnostou	et	 al,	
2016).	 Interestingly	also,	 intra-tumoural	neoantigen	heterogeneity	has	been	shown	
to	 affect	 response	 to	 immune	 checkpoint	 inhibitors,	with	 higher	 response	 rates	 in	
tumours	 predicted	 to	 have	 a	 high	 clonal	 neoantigen	 burden	 (McGranahan	 et	 al,	
2016).	 It	 is	 possible	 that	 in	 inherently	 immunoevasive	 tumours,	 significantly	
increasing	mutational	load	(i.e.	antigenicity)	lowers	the	threshold	of	immunogenicity	
required	to	result	in	responses	to	immune	checkpoint	inhibition	and	pembrolizumab	
has	 recently	 received	accelerated	FDA	approval	 for	 the	 treatment	of	microsatellite	
instability-high	 (MSI-H)	or	mismatch	 repair	deficient	 (dMMR)	 tumours,	 irrespective	
of	tumour	type.		
	
Similarly	 to	 mismatch	 repair	 deficiency,	 defects	 in	 other	 components	 of	 the	 DNA	
damage	response	also	result	in	unique	mutational	signatures	in	tumours	(Alexandrov	
et	 al,	 2013).	 Breast	 tumours	 from	 patients	 with	 germline	 mutations	 in	 BRCA1	 or	
BRCA2	harbor	a	greater	number	of	clonal	mutations	compared	to	BRCA1/2	wildtype	
tumours	 for	 example	 (Nik-Zainal	 et	 al,	 2012)	 and	 in	 a	 study	 of	 gastric	 cancer,	 an	
association	between	ATM	loss	and	microsatellite	instability	has	been	demonstrated	
(Kim	et	al,	2014).	Whether	these	observations	translate	into	increased	responses	to	
immune	checkpoint	inhibitors	has	yet	to	be	demonstrated.	Interestingly	however,	in	
NSCLC,	mutations	in	DNA	repair	genes	such	as	POLD1,	POLE,	BRCA2,	PRKDC,	MSH2,	
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RAD51C,	LIG3	and	RAD17	were	frequently	identified	in	tumours	with	high	mutational	
burden,	the	majority	of	which	had	a	partial	response	to	pembrolizumab	(Rizvi	et	al,	
2015).	As	well	as	having	high	mutational	loads,	DDR	deficient	tumours	may	also	have	
unique	 immunological	 characteristics	 and	 at	 least	 BRCA1/2	 mutant	 tumours	 have	
been	shown	to	be	associated	with	higher	 levels	of	tumour	 infiltrating	 lymphocytes,	
increased	secretion	of	lymphocyte	attractants	(eg,	C-X-C	motif	ligand	[CXCL]	10)	and	
upregulation	 of	 immune	 suppressive	 ligands	 such	 as	 PD-L1	 (Mulligan	 et	 al,	 2014;	
Strickland	et	al,	2016).		
	
DNA-damaging	 agents	 are	 mutagenic,	 as	 demonstrated	 by	 the	 increased	 risk	 of	
secondary	 cancers	 following	 treatment	 with	 radiotherapy	 or	 chemotherapeutics	
such	 as	 etoposide	 and	 also,	 by	 the	 mutational	 signatures	 associated	 with	 some	
treatments	 (Alexandrov	et	 al,	 2013;	Murugaesu	et	 al,	 2015).	 Inhibition	 of	 PARP	 in	
sensitive	 tumour	 cells,	 for	 example	 those	 carrying	 mutations	 in	 the	 BRCA	 gene,	
results	 in	 accumulating	 levels	 of	 DNA	 damage	 and	 genomic	 instability,	 ultimately	
resulting	in	cell	death	(Farmer	et	al,	2005);	and	one	may	extrapolate	that	in	cells	that	
survive,	the	neoantigen	load	is	 likely	to	rise,	thereby	diversifying	epitopes	available	
for	recognition	by	T	cells	(epitope	spreading)	(Jackaman	et	al,	2012).	Importantly,	the	
mutagenic	 potential	 of	 DNA	 damaging	 agents	 likely	 differs	 across	 classes	 of	 drugs	
and	 it	 cannot	 be	 assumed	 that	 all	 chemotherapy	will	 increase	 neoantigen	 load	 in	
tumours	equally.	Interestingly,	the	heterogenous	increase	in	mutations	that	arise	as	
a	result	of	treatment	with	DNA	damaging	drugs	such	as	anthracyclines	and	platinum-
containing	 regimens,	 whilst	 increasing	 the	 sub-clonal	 neoantigen	 population,	 may	
not	result	in	the	clonal	neoantigen	presentation	required	for	significant	sensitivity	to	
immune	checkpoint	inhibition	(Murugaesu	et	al,	2015;	McGranahan	et	al,	2016).		
	
2. Increasing	antigen	presentation		
	
A	 number	 of	 chemotherapies,	 including	 gemcitabine,	 oxaliplatin	 and	
cyclophosphamide	 have	 been	 shown	 to	 increase	 antigen	 presentation	 by	 up-
regulating	MHC	class	I	expression	on	tumour	cells	(Liu	et	al,	2010).	The	same	agents	
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have	 also	 been	 shown	 to	 promote	 dendritic	 cell	maturation,	 priming	 them	 for	 an	
adaptive	 immune	 response	 (Liu	 et	 al,	 2010).	 Cyclophosphamide	 in	 particular	 has	
been	shown	to	expand	dendritic	cell	precursor	populations,	which	promotes	efficient	
T	cell	priming	(Sistigu	et	al,	2011).		
	
3. Immunogenic	cell	death			
Neoantigen	exposure	is	insufficient	in	isolation	to	stimulate	an	adaptive	immune	
response	(Galluzzi	et	al,	2016).	The	context	for	neoantigen	exposure	seems	to	be	
critical,	as	demonstrated	by	the	fact	that	many	neoantigens	with	the	potential	to	
stimulate	T	cell	responses	in	healthy	patients	go	unnoticed	in	a	host	with	cancer	
(Strønen	et	al,	2016).	Immunogenicity	and	resulting	immunological	memory	requires	
antigenicity	–	exposure	of	neoantigens,	as	well	as	adjuvanticity	–	the	presence	of	a	
danger	signal	that	activates	the	innate	immune	system	(Galluzzi	et	al,	2016).	Danger	
signals	from	tumours	are	provided	by	damage	associated	molecular	patterns	
(DAMPs);	host	molecules	that	are	released	from	dying	cells.	Release	of	DAMPs	
stimulate	the	recruitment	of	APCs	to	sites	of	immunogenic	cell	death	(ICD),	where	
they	process	and	present	tumour	neoantigens,	thereby	priming	an	adaptive	immune	
response.		
	
The	gold	standard	for	measuring	levels	of	ICD	utilise	vaccination	experiments,	
whereby	murine	dying	cells	are	injected	into	immunocompetent	syngeneic	mice,	
which	are	later	challenged	with	living	cancer	cells	of	the	same	type	(Kepp	et	al,	
2014).	Some	chemotherapeutics	can	induce	ICD,	including	for	example:	
anthracyclines	(doxorubicin,	epirubicin	and	idarubicin),	mitoxantrone,	oxaliplatin,	
cyclophosphamide,	and	bortezomib	(Bezu	et	al,	2015).	The	danger	signals	or	DAMPs	
released	during	chemotherapy-induced	ICD	include:	plasma	membrane	exposure	of	
endoplasmic	reticulum	chaperones	such	as	calreticulin	(CALR),	secretion	of	ATP,	
release	of	double	stranded	DNA	resulting	in	activation	of	stimulator	of	interferon	
genes	(STING)	and	release	of	type	I	interferon	and	pro-inflammatory	cytokines	
(Barber,	2015),	secretion	of	CXC-chemokine	ligand	10	(CXCL10),	as	well	as	the	
release	of	high-mobility	group	box	1	(HMGB1)	and	annexin	A1	(ANXA1)	(Galluzzi	et	
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al,	2016).	STING	activation	in	particular	appears	to	be	highly	relevant	to	the	immune	
response	to	DNA	damaging	agents	whereby	DNA	accumulation	in	the	cytosol	results	
in	type	I	interferon	production	due	to	stimulation	of	the	STING	pathway	(Kondo	et	al,	
2013;	Härtlova	et	al,	2015;	Erdal	et	al,	2017)	
	
Interestingly,	the	level	of	ICD	is	not	necessarily	equal	across	classes	of	
chemotherapeutics,	as	cisplatin	for	example,	does	not	induce	ICD	like	oxaliplatin,	
due	to	a	failure	to	release	CALR	(Bezu	et	al,	2015).	In	fact,	attenuation	of	any	
element	of	DAMP	signalling	results	in	a	failure	to	elicit	ICD	as	has	been	shown	with	a	
number	of	chemotherapeutics	in	routine	clinical	use	(Bezu	et	al,	2015).	Using	
combinatorial	strategies,	it	may	be	possible	to	restore	ICD,	for	example,	ER-stressing	
agents	such	as	pyridoxine,	have	the	ability	to	render	cisplatin	treatment	
immunogenic	in	pre-clinical	studies	(Bezu	et	al,	2015).	It	is	also	worth	noting	that	in	
the	context	of	treatment	with	bone	fide	immunogenic	chemotherapy,	to	date	there	
does	not	appear	to	be	any	evidence	that	mutational	load	affects	ICD	(Galluzzi	et	al,	
2016).	
	
4. Changing	the	cytokine	milieu	within	the	TME	
	
As	 discussed	 further	 below,	 in	 response	 to	 DNA	 damaging	 chemotherapy,	 the	
cellular	DNA	damage	response	(DDR),	coordinates	signalling	pathways	that	result	in	
the	release	of	pro-inflammatory	cytokines	such	as	NF-κB	and	IFN-α	 (Chatzinikolaou	
et	 al,	 2014).	 The	 release	 of	 cytokines	 into	 the	 extracellular	 space	 has	 a	 bystander	
effect	 on	 neighboring	 cells	 that	 results	 in	 an	 immunogenic	 TME	 (Malaquin	 et	 al,	
2015).	Interestingly,	in	mice	harboring	defects	in	the	nucleotide	excision	DNA	repair	
pathway	 (NER),	 DNA	 damage	 leads	 to	 chronic	 auto-inflammatory	 signaling	
(Karakasilioti	 et	 al,	 2013).	 Persistent	 DNA	 damage	 results	 in	 transcriptional	
derepression	 of	 proinflammatory	 cytokines	 such	 as	 TNFα	 and	 IL-6,	 in	 a	 manner	
dependent	on	the	apical	DDR	signaling	kinases	Ataxia	Telangiectasia	Mutated	(ATM)	
and	Ataxia	Telangiectasia	and	Rad3-Related	Protein	(ATR)	(Karakasilioti	et	al,	2013).		
A	 similar	 phenomenon	 has	 also	 been	 demonstrated	 following	 treatment	 with	 the	
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PARP	 inhibitor	 BMN	 673.	 Treatment	 of	 Brca1-/-	mice	 with	 BMN	 673,	 resulted	 in	
significantly	 increased	 levels	 of	 IFN-γ	 and	 TNF-α,	 as	 well	 as	 increased	 levels	 of	
peritoneal	CD8+	and	NK	cells	(Huang	et	al,	2015).	In	pre-clinical	combination	studies,	
CTLA-4	blockade	has	been	shown	to	synergise	with	PARP	inhibition	in	Brca1	deficient	
mouse	models	of	ovarian	cancer,	in	a	manner	dependent	on	IFN-γ secretion	into	the	
TME	 (Higuchi	et	al,	2015).	CTLA-4	blockade	has	also	been	shown	to	synergise	with	
ixabepilone,	etoposide,	and	gemcitabine	treatment	 in	pre-clinical	mouse	models	of	
cancer,	although	the	mechanism	for	this	synergy	has	not	been	fully	described	(Jure-
Kunkel	et	al,	2013).	In	a	study	of	DDR	deficient	breast	cancer	cells	(as	defined	using	a	
molecular	 signature	 of	 DDR	 deficiency),	 DDR	 deficiency	 was	 associated	 with	
increased	production	of	chemokines	CXCL10	and	CCL5,	both	of	which	are	important	
for	PBMC	chemotaxis	(Parkes	et	al,	2017).		All	these	studies	suggest	that	generating	
chronic	 DNA	 damage	 in	 cancer	 cells,	 particularly	 those	 deficient	 in	 DNA	 repair,	
generates	a	pro-inflammatory	environment	and	immunogenic	tumours.	
	
For	many	DNA	damaging	agents,	 it’s	difficult	 to	tease	apart	effects	on	the	 immune	
system	that	occur	indirectly	as	a	result	of	a	DDR-induced	‘stress’	response	vs	those	
occurring	 independently	 of	DNA	damage.	 Some	 chemotherapies	 are	 recognized	 to	
be	directly	immunomodulatory	however,	with	cyclophosphamide	perhaps	being	the	
best	example	in	this	regard.		Low	dose	cyclophosphamide	treatment	results	in	higher	
levels	 of	 IFN-γ	 and	 IL-2,	 both	 TH1	 cytokines	 that	 promote	 cell-mediated	 immune	
activities	(Sistigu	et	al,	2011).	
5. Indirectly	lifting	immunosuppression	-	downregulation	of	MDSCs	and	
Tregs	
	
Tregs	are	essential	for	the	maintenance	of	self-tolerance	and	increasing	numbers	of	
Treg	 cells	 in	 the	 TME,	 is	 one	 mechanism	 by	 which	 tumours	 evade	
immunosurveillance	 (Motz	 et	 al,	 2014).	 Cyclophosphamide	 treatment	 has	 been	
shown	to	enhance	the	effects	of	anti-tumour	HER-2/neu	(neu)-targeted	vaccines	 in	
neu-N	 mice,	 at	 least	 in	 part	 through	 depleting	 Treg	 levels	 (Ercolini	 et	 al,	 2005).	
Similarly,	in	mouse	models	of	glioblastoma,	low	dose	temozolamide	has	been	shown	
to	 result	 in	depletion	of	 the	Treg	cell	population	 (Banissi	et	al,	2009).	 Inhibition	of	
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the	 MDSC	 population	 by	 chemotherapy	 such	 as	 gemcitabine	 and	 5-FU	 may	 also	
contribute	 positively	 to	 anti-tumour	 immune	 responses	 following	 treatment	 with	
DNA	damaging	agents	(Suzuki	et	al,	2005;	Vincent	et	al,	2010).	
6. Effects	on	PD-1/PD-L1	expression	
	
PD-L1	expression	is	associated	with	a	poor	prognosis	across	a	range	of	tumour	types	
(Luo	&	Fu,	2016).	Several	studies	have	demonstrated	that	chemotherapy	leads	to	an	
upregulation	of	PD-L1	expression	in	tumours	and	in	some	cases,	this	has	been	linked	
to	chemotherapy	resistance	(Yan	et	al,	2016;	Zhang	et	al,	2016).	Other	studies	have	
reported	 a	 downregulation	 of	 PD-L1	 expression	 on	 tumour	 cells	 following	
chemotherapy	(Sheng	et	al,	2016)	or	a	redistribution	of	PD-L1	from	the	cell	surface	
to	 nuclear	 membrane	 (Ghebeh	 et	 al,	 2010).	 Common	 to	 all	 these	 studies,	 is	 the	
notion	 that	 PD-L1	 expression	 is	 dynamic	 and	 can	 be	 affected	 by	 DNA	 damaging	
agents.	Multiple	factors	are	 likely	to	 influence	PD-L1	expression	however,	 including	
type	 of	 chemotherapeutic	 agent,	 tumour	 type,	 baseline	 PD-L1	 expression	 and	
response	to	treatment.	The	overriding	hypothesis	 is	that	for	several	DNA	damaging	
agents,	 immune-mediated	clearance	of	the	tumour	contributes	to	chemosensitivity	
and	blockade	of	PD-1/PD-L1	signalling	my	therefore	reverse	resistance.	
	
In	summary,	whilst	many	DNA-damaging	agents/immunotherapy	combinations	
might	be	additive	in	their	anti-tumour	effects,	synergy	may	only	be	achieved	with	
clear	biology-driven	combinations	that	results	in	ICD	and	optimal	priming	of	the	host	
immune	system,	and	micro-environment	cytokine	milieu.		
Enhancing	DNA	damage	using	inhibitors	of	DDR	signaling		
Following	 DNA	 damage	 in	 cells,	 the	 DNA	 damage	 response	 (DDR)	 engages	 a	
spectrum	of	signaling	pathways	that	result	in	downstream	activation	of	a	number	of	
effector	 processes	 including:	 DNA	 repair,	 cell	 cycle	 checkpoint	 activation	 and	
transcriptional	 regulation,	 amongst	 others	 (Jackson	 &	 Bartek,	 2009).	 Deficiency	 in	
the	DDR	is	a	hallmark	of	cancer	and	germline	or	somatic	mutations	in	DDR	genes	can	
be	identified	across	a	range	of	tumour	types	(Kandoth	et	al,	2013).		
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Inhibiting	the	DNA	damage	response	(DDR)	in	tumours	is	a	promising	clinical	strategy	
and	a	number	of	DDR	inhibitors	are	now	in	clinical	development	(Brown	et	al,	2017).	
DDR	 inhibitors	 have	 the	 potential	 to	 increase	 mutational	 burden	 in	 tumours,	
particularly	 in	 cancers	 with	 high	 levels	 of	 endogenous	 DNA	 damage	 or	 in	
combination	 with	 exogenous	 DNA	 damaging	 agents.	 In	 addition,	 combining	 DNA	
damaging	 agents	 with	 DNA	 repair	 inhibitors	 naturally	 results	 in	 greater	 and	more	
persistent	DNA	damage	and	there	is	intense	interest	in	how	this	may	promote	STING	
activation	 and	 expression	 of	 TH1	 cytokines	 (Härtlova	 et	 al,	 2015).	 Several	 trials	
investigating	 DNA	 repair	 inhibition	 in	 combination	 with	 immune	 checkpoint	
inhibition	are	ongoing	(Brown	et	al,	2017)	(Table	2),	however,	we	must	be	mindful	of	
the	fact	that	an	intact	DDR	plays	an	important	role	in	immunity	and	DDR	inhibition	
has	 the	 potential	 to	 attenuate	 rather	 than	 stimulate	 an	 immune	 response	
(Chatzinikolaou	et	al,	2014).		
	
Many	 key	 players	 in	 the	 DDR	 have	 fundamental	 roles	 in	 innate	 and	 adaptive	
immunity	(Ioannidou	et	al,	2016),	for	example:	Dna-pkcs	knockout	mice	have	severe	
combined	 immunodeficiency	 due	 to	 a	 defect	 in	 V(D)J	 recombination	 and	 Ataxia	
Telangiectasia,	 a	 syndrome	 arising	 due	 to	 germline	 mutations	 in	 ATM	 is	
characterized	in	part	by	an	albeit	variable	 immunodeficient	phenotype.	 In	fact,	 it	 is	
widely	 accepted	 that	 mechanisms	 of	 DNA	 repair	 and	 immunity	 have	 evolved	 in	
parallel	 (Ioannidou	 et	 al,	 2016).	 An	 intact	 DDR	 is	 essential	 for	 proficient	 innate	
immune	activation,	following	for	example,	the	presence	of	foreign	viral	DNA	in	cells	
and	in	particular,	results	in	expression	of	ligands	for	the	activating	natural	killer	(NK)	
cell	receptor	NKG2D	as	well	as	release	of	Type	I	interferons	and	nuclear	factor	kappa	
B	(NF-κB)	which	promote	antigen	presentation	(Chatzinikolaou	et	al,	2014;	Tang	et	
al,	 2014).	 The	 DDR	 therefore	 provides	 an	 essential	 link	 between	 the	 detection	 of	
nuclear	DNA	damage	and	an	appropriate	 immune	response	(Ioannidou	et	al,	2016;	
Nakad	&	 Schumacher,	 2016).	 Given	 the	 pro-inflammatory	 effects	 of	 DDR	 signaling	
following	DNA	 damage,	 inhibiting	 these	 processes	 has	 the	 potential	 to	 antagonize	
the	 effects	 of	 immune	 checkpoint	 inhibitors.	 In	 addition,	many	 key	 players	 in	 the	
DDR	function	in	multiple	cellular	processes	beyond	DNA	repair	(Blackford	&	Jackson,	
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2017)	and	therefore	clinical	combination	studies	require	careful	consideration,	along	
with	appropriate	 control	 arms	and	 translational	 studies	 to	 truly	 test	 the	 long-term	
benefit	of	combination	vs	monotherapy	strategies.	
	
Of	the	DDR	inhibitors	in	clinical	development,	PARP	inhibitors	are	most	studied	and	
are	now	licensed	for	clinical	use	in	ovarian	cancer	(Brown	et	al,	2016).	As	well	as	its	
role	 in	DNA	 repair,	 PARP	has	 a	well-established	pro-inflammatory	 role	 and	 in	 pre-
clinical	 models,	 PARP	 inhibitors	 attenuate	 chronic	 inflammatory	 and	 autoimmune	
conditions	 in	 multiple	 organs	 (Rosado	 et	 al,	 2013).	 	 Recently,	 it	 has	 also	 been	
demonstrated	that	mice	deficient	for	Parp1	and	Parp2	have	a	compromised	immune	
response	 due	 to	 defective	 thymocyte	 maturation	 with	 diminished	 numbers	 of	
peripheral	CD4+	and	CD8+	T	 cells	 (Navarro	et	al,	 2017).	 Treatment	of	homologous	
recombination	deficient	tumours	with	PARP	inhibitors,	particularly	those	with	BRCA1	
or	BRCA1	mutations,	generates	significant	levels	of	DNA	damage	however	(Farmer	et	
al,	 2005)	 and	 there	 may	 be	 a	 threshold,	 above	 which	 the	 DNA	 damage-induced	
stress	signals	overwhelm	the	otherwise	anti-inflammatory	effects	of	PARP	inhibition.	
In	 addition,	 it’s	 possible,	 although	 not	 proven	 that	 in	 the	 context	 of	 synthetic	
lethality,	 PARP	 inhibition	 is	 pro-inflammatory	 due	 to	 overwhelming	 tumour	 cell	
death.	In	BRCA1/2	wild	type	cells,	however,	PARP	inhibitors	may	attenuate	immune	
signaling	 and	 it	 will	 be	 particularly	 interesting	 to	 determine	 whether	 toxicity	 of	
immune-checkpoint	 inhibitors	 in	 combination	with	 PARP	 inhibitors	 is	 reduced	 as	 a	
result.		
The	challenges	of	combining	DNA	damaging	agents	with	
immune	checkpoint	inhibitors	
	
1. Choice	of	agent	
	
As	 detailed	 in	 this	 review,	 it	 is	 clear	 that	 DNA	 damaging	 agents	 are	 not	 equally	
immunogenic	 and	 therefore	 choice	 of	 combination	 therapies	 with	 immune	
checkpoint	inhibitors	needs	to	be	carefully	considered.	The	strategy	may	also	differ	
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depending	 on	 the	 treatment,	 with	 agents	 that	 result	 in	 immunogenic	 cell	 death	
perhaps	requiring	less	or	different	immune	stimulation	to	those	that	don’t.	In	Brca1-
deficient	mouse	models	of	ovarian	cancer	for	example,	inhibition	of	CTLA-4,	but	not	
PD-1/PD-L1	 synergised	 with	 PARP	 inhibitor	 treatment	 (Higuchi	 et	 al,	 2015).	 It’s	
possible	that	 in	non-immunogenic	tumours,	or	 following	treatment	with	drugs	that	
do	not	result	in	ICD,	the	repertoire	of	anti-tumour	immune	related	responses	needs	
to	be	broadened,	rather	than	just	stimulated	(Kvistborg	et	al,	2014).	
	
2. DOSE				
Largely	speaking,	chemotherapy	is	employed	at	the	maximum	tolerated	dose	(MTD),	
where	 it	can	be	potently	myelosuppressive,	depleting	the	 immune	related	cells	we	
are	 hoping	 to	 stimulate.	 Tumour	 cell	 death	 results	 in	 the	 release	 of	 neoantigens	
however,	 into	 the	 TME,	 as	 well	 as	 release	 of	 ‘danger	 signals’	 that	 stimulate	
immunological	memory.	Carefully	designed	trials	therefore	need	to	consider	testing	
whether	 maximal	 tumour	 cell	 death	 (at	 the	 MTD)	 should	 be	 compromised	 in	 an	
effort	to	spare	immunoreactive	T	cell	populations.	It’s	possible	that	lower	doses	may	
offer	 greater	 immune	 modulation	 and	 high	 dose	 cyclophosphamide	 for	 example,	
depletes	dendritic	cell	precursors,	whereas	lower	doses	increase	dendritic	cell	pools	
and	 promote	 T	 cell	 priming	 (Sistigu	 et	 al,	 2011).	 With	 respect	 to	 stimulation	 of	
vaccine	 responses,	 low	 dose	 cyclophosphamide	 has	 a	 narrow	 therapeutic	 window	
(Emens	 et	 al,	 2009).	 Similarly,	 low	 dose	 temozolamide	 (TZ)	 but	 not	 high	 dose	 TZ	
results	 in	 depletion	 of	 the	 Treg	 cell	 population	 (Banissi	et	 al,	 2009).	 In	 pre-clinical	
studies	 of	 tumour-specific	 vaccines,	 chemotherapy	 administration	 at	 a	 dose	 just	
above	 that	 which	 starts	 to	 cause	 cytopenias	 was	 optimal	 for	 enhancing	 vaccine	
efficacy,	suggesting	that	dosing	just	below	the	MTD	may	be	optimal	(Machiels	et	al,	
2001).		
	
For	 DNA	 damaging	 compounds	 that	 are	 clearly	 immunomodulatory	 beyond	 their	
ability	 to	 cause	 ICD,	 there	 is	 some	 suggestion	 that	metronomic	 regimens	will	 lend	
themselves	 towards	 combination	 strategies	with	 immune	 checkpoint	 inhibitors.	 At	
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least	 for	 some	 DNA	 damaging	 agents	 such	 as	 gemcitabine,	 however,	 cell	 death	
appears	 important	 for	 immunogenicity	 (Nowak	 et	 al,	 2003).	 In	 a	 study	 utilising	
animal	 models	 of	 mesothelioma,	 gemcitabine	 lost	 its	 immunogenicity	 on	
chemoresistant	 cell	 lines,	 when	 apoptosis	 did	 not	 occur	 (Nowak	 et	 al,	 2003).	
Assuming	in	this	instance,	that	the	immunophenotype	of	chemoresistant	vs	sensitive	
tumours	are	equal	(which	may	not	necessarily	be	the	case),	cell	death	was	important	
for	 tumour-antigen	 specific	 leucocyte	 proliferation	 (Nowak	 et	 al,	 2003).	 Certainly,	
pre-clinical	 and	 early	 phase	 clinical	 studies	 should	 investigate	 optimal	 immune-
modulating	 doses	 of	 DNA	 damaging	 agents	 by	 utilising	 pharmacodynamic	 (PD)	
biomarkers	of	changes	in	the	tumour	immune	profile.	
	
3. Scheduling	and	sequencing	of	combinations	
	
Most,	 if	 not	 all	 anti-cancer	 combination	 therapies	 are	 currently	 administered	
concurrently	and	 in	 the	 large	part,	 the	optimal	 sequencing	of	agents	has	not	been	
fully	explored.	To	maximise	the	efficacy	of	immune	checkpoint	inhibitors,	it	might	be	
advantageous	to	prime	the	immune	system,	administering	DNA	damaging	agents	up	
front,	and	data	from	a	number	of	studies	now	support	this.	Administration	of	DTIC	
one	 day	 before	 vaccination	 with	 a	 combination	 gp100	 and	 melanoma	 specific	
antigen	vaccine	resulted	in	a	significantly	improved	long	lasting	memory	CD8+	T-cell	
response	 compared	 to	 vaccine	 alone	 (Nisticò	 et	 al,	 2009).	 In	 a	 phase	 II	 trial	 of	
carboplatin	 and	 paclitaxel	 (carbo/taxol)	 +/-	 concurrent	 or	 phased	 ipilimumab	 (ipi),	
only	 phased	 treatment	 (carbo/taxol	 for	 2	 cycles	 followed	 by	 carbo/taxol/ipi	 for	 4	
cycles)	 showed	 an	 improved	 immune-related	 (ir)	 PFS	 benefit	 over	 chemotherapy	
alone	and	a	trend	towards	an	OS	benefit	in	this	arm	in	patients	with	small	cell	lung	
cancer	 (SCLC)	 (Reck	 et	 al,	 2013).	 In	 this	 study,	 there	was	 no	 benefit	 between	 the	
arms	when	considering	a	non-immune	related	PFS	end-point	(Reck	et	al,	2013).	In	a	
similar	study	in	NSCLC	however,	carbo/taxol	plus	phased	ipilimumab	demonstrated	a	
modest	improvement	in	irPFS	and	PFS	over	chemotherapy	alone	(Lynch	et	al,	2012).	
In	 a	 mouse	 model	 of	 mesothelioma,	 concurrent	 administration	 of	 anti-CTLA-4	
blocking	 antibody	 and	 gemcitabine	 was	 superior	 in	 terms	 of	 overall	 survival	
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compared	to	sequential	administration	of	either	anti-CTLA	antibody	or	gemcitabine	
first	 (Lesterhuis	 et	 al,	 2013).	 These	 studies	 suggest	 that	 upfront	 treatment	 with	
chemotherapy,	 followed	 by	 a	 period	 of	 concurrent	 treatment	 with	 chemotherapy	
and	 immune	 checkpoint	 inhibition	 might	 be	 optimal,	 however,	 further	 studies	
testing	proof	of	concept	data	and	incorporating	PD	endpoints	are	required	in	order	
to	 truly	 establish	 the	 optimal	 scheduling	 in	 the	 clinic.	 Testing	 the	 immunological	
effects	of	 chemotherapy	 combinations	 in	murine	 studies	might	not	provide	all	 the	
answers,	 but	 perhaps	 it	 should	 be	 a	 simple	 precursor	 to	 strengthen	 the	 scientific	
rationale	 of	 a	 large	 and	 costly	 clinical	 trial.	 Similarly,	 a	 case	 could	 be	 made	 for	
randomised	 biomarker	 proof-of-concept	 phase	 2	 trials	 to	 guide	 scheduling	 and	
immunomonitoring	 before	 embarking	 on	 phase	 3	 studies,	 albeit	 knowing	 that	
endless	combinations	and	schedules	could	potentially	be	tested.		
7. Toxicity		
	
Published	 and	 presented	 data	 from	 clinical	 trials	 combining	 DNA	 damaging	
chemotherapy	and	immune	checkpoint	inhibitors	suggests	that	these	agents	can	be	
safely	 combined.	 Given	 the	 non-overlapping	 toxicity	 of	 DNA	 damaging	
chemotherapy	 and	 immune	 checkpoint	 inhibition	monotherapy,	 combination	 trials	
have	 been	 able	 to	 achieve	 optimal	 doses	 of	 both	 agents.	 Foreseeable	 challenges	
surround	the	practicalities	of	delivering	both	agents	however.	Many	DNA	damaging	
chemotherapy	 regimens	 incorporate	 significant	 doses	 of	 corticosteroids,	 either	 to	
limit	 hypersensitivity	 reactions,	 or	 as	 part	 of	 the	 anti-emetic	 regimen.	 The	
immunosuppressive	effects	of	steroids	have	the	potential	to	attenuate	the	effects	of	
the	 immune	 checkpoint	 inhibitors,	 although	 there	 is	 limited	 and	 inconclusive	
evidence	 to	determine	how	detrimental	 steroid	use	will	be	on	overall	efficacy.	For	
those	 symptoms	 that	 do	 overlap,	 such	 as	 diarrhoea,	 fatigue	 and	 myalgias,	
determining	 the	 likely	 causative	 agent	will	 be	 challenging	 and	will	 have	 significant	
implications	 on	 the	 overall	management.	 In	 particular,	 oncologists	will	 be	 nervous	
about	 reducing	 the	 dose	 intensity	 of	 chemotherapy,	 particularly	 in	 an	 adjuvant	 or	
neo-adjuvant	 setting,	which	might	be	difficult	 to	avoid	when	managing	 concurrent	
immune	related	toxicities.	
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Combining	DNA	damaging	agents	and	immunotherapy	in	the	
clinic		
There	are	now	>200	clinical	trials	listed	on	clinicaltrials.gov	that	are	testing	immune-
checkpoint	 inhibitors	 in	 combination	 with	 DNA	 damaging	 chemotherapies	 (Figure	
2a).	 Between	 the	 four	 anti-PD-1/PD-L1	agents	 that	 are	most	 advanced	 in	 terms	of	
clinical	 development,	 it	 would	 appear	 that	 every	 standard	 of	 care	 chemotherapy	
regimen,	 in	 every	 tumour	 type	 is	 being	 tested	 in	 combination	 with	 at	 least	 one	
immune	 checkpoint	 inhibitor	 (Figure	 2a).	 There	 has	 been	 an	 almost	 exponential	
increase	 in	 the	 number	 of	 immunotherapy/chemotherapy	 trials	 being	 conducted	
over	 the	 last	 12-24	months	 and	 only	 time	will	 tell	whether	 in	 being	 so	 hasty,	 the	
scramble	to	registration	will	truly	pay	off.	To	our	knowledge,	of	those	trials	that	are	
published	or	 that	have	preliminary	data	available,	combination	treatment	with	PD-
1/PD-L1	 inhibitors	and	DNA	damaging	chemotherapy	certainly	has	 the	potential	 to	
be	superior	to	chemotherapy	alone	(Harris	et	al,	2016;	Langer	et	al,	2016).	We	have	
yet	to	see	an	immunotherapy	monotherapy	control	arm	however	and	therefore	it	is	
difficult	to	determine	the	proportion	of	patients	that	are	truly	benefitting	from	the	
combination.	 Equally,	 it	 is	 too	 early	 to	 be	 certain	 of	 whether	 long-term	 survival	
benefit	 is	 improved	 using	 combination	 treatments	 upfront.	 With	 regards	 to	
immunotherapy/DDR	 inhibitor	 combination	 studies,	 a	 phase	 I	 trial	 of	 Durvalumab	
(PDL1	inhibitor)	 in	combination	with	olaparib	(PARP	inhibitor)	has	shown	promising	
anti-tumour	 activity,	 with	 the	 combination	 proving	 to	 be	 safe;	 although	
haematological	 toxicity	 was	 observed	 more	 frequently	 compared	 to	 historical	
olaparib	 monotherapy	 studies	 (Lee	 et	 al,	 2017).	 Further	 studies	 to	 evaluate	 the	
clinical	effectiveness,	as	well	as	 translation	work	 to	understand	 the	synergy	of	 this	
combination	will	be	of	great	interest.	
	
Immunotherapy	 biomarkers	 have	 been	 extensively	 reviewed	 previously	 and	 a	
detailed	 discussion	 here	 is	 beyond	 the	 scope	 of	 this	 review	 (Gibney	 et	 al,	 2016).	
Needless	 to	 say	 however,	 utilizing	 PD	 biomarkers	 should	 be	 a	 compulsory	
component	of	early	phase	combination	studies	in	order	to	determine	optimal	doses	
and	 scheduling	 –	 in	 particular	 identifying	 robust	 biomarkers	 of	 ICD	 and	 cytokine	
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signatures	of	immune	activation.	Equally,	determining	early	biomarkers	of	response	
should	 be	 incorporated	 into	 all	 trials,	 as	 effective	 patient	 selection	 will	 maximize	
efficacy	 and	will	 also	 facilitate	 decision	making	 regards	 continuation	 of	 treatment	
(Lesterhuis	et	al,	2017).	
Conclusion	
	
Tumour	 immunobiology	 is	 complex	 and	 the	 extensive	 network	 of	 overlapping	
mechanisms	 utilised	 by	 tumours	 to	 evade	 immunosurveillance	 makes	 optimally	
targeting	 this	 process	 a	 considerable	 challenge.	 Combining	 DNA	 damaging	
chemotherapy	with	immune	checkpoint	inhibitors	has	the	potential	to	reverse	many	
of	 these	 immunoevasive	 strategies.	Many	 unanswered	 questions	 remain	 however,	
including	 choosing	 the	 optimal	 agents,	 determining	 effective	 doses	 and	 schedules	
and	 managing	 toxicity.	 Establishing	 clinically	 measurable	 pharmacodynamic	
biomarkers,	as	well	as	robust	biomarkers	of	response	to	combination	treatments	is	
going	to	be	essential.	
	
Whilst	DNA	damaging	chemotherapy	undeniably	has	the	potential	to	synergise	with	
immune	checkpoint	inhibitors	in	the	clinic,	the	scientific	rationale	is	not	immediately	
obvious	 in	 many	 ongoing	 clinical	 studies.	 Many	 chemotherapy/immunotherapy	
combinations	 are	 entering	 late	 phase	 clinical	 studies	 following	 only	 small	 safety-
orientated	 phase	 I	 trials,	 with	 limited	 or	 absent	 investigation	 of	 appropriate	 PD	
biomarkers.	As	we	are	discovering,	there	is	a	sliding	scale	of	immunogenicity	within	
tumours	(Blank	et	al,	2016;	Kingwell,	2016).	At	one	end	of	the	scale,	‘inflammatory’	
tumours	may	 need	minimal	 immune	 stimulation,	 requiring	 combination	 strategies	
only	 upon	 resistance	 to	 immune	 checkpoint	 inhibition.	 At	 the	 other	 end	 of	 the	
spectrum,	 an	 ‘immune	 desert’	 designates	 tumours	 that	 are	 likely	 to	 require	
immunological	 priming	 in	 conjunction	 with	 maximal	 immune	 stimulation	 to	 see	
benefit	 (Figure	 2b).	 It	 Is	 essential	 that	 we	 design	 trials	 that	 incorporate	 not	 only	
patient	 selection	 biomarkers,	 but	 also	 pharmacodynamic	 biomarkers	 that	
consolidate	our	understanding	of	the	biology,	confirm	or	refute	our	hypotheses	and	
result	 in	 the	 optimal	 combinations,	 in	 the	 optimal	 sequence	 and	 at	 the	 optimal	
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doses.		Race	to	registration	is	threatening	a	careful	and	considered	approach,	which	
risks	us	never	realising	the	true	potential	of	these	combinations.	
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Figure	and	Table	legends		
Table	1:	Immune	checkpoint	inhibitors	with	a	licence	for	use	in	cancer.	Food	and	Drug	administration	(FDA);	European	medicines	agency	(EMA);	National	institute	for	health	and	care	excellence	(NICE).		
Table	2:	Ongoing	combination	trials	with	DDR	and	immune	checkpoint	inhibitors	(www.clinicaltrials.gov).		
Figure	1:	Mechanisms	by	which	DNA	damaging	agents	affect	the	immunogenicity	of	tumours.	See	text	for	details.		
Figure	2	(A):	Chemotherapy	combination	trials	with	current	PD-1	and	PD-L1	checkpoint	inhibitors	as	registered	with	www.clinicaltrials.gov.	Abbreviations:	HNSCC:	Head	and	neck	squamous	cell	cancer,	NSCLC:	Non-small	cell	lung	cancer,	SCLC:	Small	cell	lung	cancer,	NHL:	Non	Hodgkins	Lymphoma,	AML:	Acute	myeloid	leukemia,	DD	agent:	DNA	damaging	agent	(B)	Proposed	biomarker-driven	approach	to	chemotherapy/immunotherapy	combination	trials.	Multiple	biomarkers	that	incorporate	profiling	of	the	tumour,	patient	and	host	immune	response	combined	to	determine	tumour	immune	phenotype	(Blank	et	al,	2016;	Hegde	et	al,	2016).	Inflamed	tumours	might	demonstrate	high	levels	of	effector	T	cells	(green),	APCs	(orange)	and	MDSCs	(blue),	with	low	PDL1	expression	and	may	respond	to	immune	checkpoint	inhibitor	(ICI)	monotherapy,	requiring	combination	treatment	with	DNA	damaging	(DD)	agents	on	progression	only.	Compare	to	the	reverse	in	immune	desert	tumours	that	may	require	priming	with	DD	agents	followed	by	concurrent	treatment	with	an	ICI.		 	
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Box	1:	Mechanisms	by	which	tumours	evade	immunosurveillance		
1.	Restricting	T	cell	accumulation	at	tumour	sites	•	The	cellular	composite	of	the	tumour	microenvironment	is	unique	compared	to	normal	stromal	tissue,	comprising	high	levels	of	cancer-associated	fibroblasts,	myeloid-derived	suppressor	cells	(MDSCs)	and	tumour-associated	macrophages.	Nitric	oxide	production	by	MDSCs	within	the	TME	results	in	nitration	of	the	chemokine	CCL2	to	N-CCL2,	which	traps	T	cells	in	the	TME,	whilst	serving	as	a	monocyte	chemoattractant	(Molon	et	al,	2011).	In	addition,	epigenetic	silencing	of	chemokines	CXCL9	and	CXCL10	inhibits	T	cell	trafficking	to	tumours	(Peng	et	al,	2015).	
2.	Promoting	T	cell	tolerance		
•	Effects	of	the	tumour	vasculature:	Immune	suppressive	Treg	cells	are	relatively	protected	against	Fas	ligand-mediated	cell	killing	due	to	having	high	expression	of	the	apoptosis	inhibitor	c-FLIP	(Motz	et	al,	2014).	High	levels	of	endothelial	Fas	ligand	(FasL)	in	tumours,	as	a	result	of	tumour-derived	vascular	endothelial	growth	factor	A	(VEGF-A),	interleukin	10	(IL-10)	and	prostaglandin	E2	(PGE2),	causes	disproportionately	high	levels	of	Treg	compared	to	CD8+	T	cell	populations	at	tumour	sites	(Motz	et	al,	2014).		
•	Indole	2,3-dioxygenase	(IDO):	The	TME	can	directly	inhibit	T	cell	expansion	through	the	production	of	indole	2,3-dioxygenase	(IDO)	which	can	be	constitutively	and	inducibly	expressed	by	dendritic	cells	(DCs),	MDSCs	and	cancer	cells	themselves	in	response	to	inflammation	(Munn	&	Mellor,	2013).	IDO	catabolizes	tryptophan	to	kynurenine	and	tryptophan	depletion	with	resulting	kynurenine	accumulation	inhibits	T	cell	proliferation	(Munn	&	Mellor,	2013).	IDO	also	promotes	the	conversion	of	naïve	T	cells	to	Treg	cells,	increases	IL-6	expression,	which	augments	MDSC	functions	and	blocks	the	reprogramming	of	Treg	to	helperlike	cells	(Munn	&	Mellor,	2016).	Overall	therefore,	IDO	is	important	for	both	controlling	inflammation,	by	pushing	APCs	towards	an	immunosuppressive	phenotype	as	well	as	creating	acquired	antigen-specific	tolerance	in	T	cells	(Munn	&	Mellor,	2016).		
3.	Inhibiting	T-cell	activation	at	tumour	sites	
•	Upregulation	of	PD-L1	expression	by	tumours:	This	contributes	to	local	suppression	of	T	cell	activation	and	evasion	of	immunosurveillance.	There	is	now	good	clinical	evidence	that	tumours	with	high	PD-L1	expression	are	more	likely	to	respond	to	PD-1	or	PD-L1	inhibitor	monotherapy	such	as	pembrolizumab	and	atezolizumab	(Herbst	et	al,	2014;	Garon	et	al,	2015),	however,	the	negative	predictive	value	of	PD-L1	expression	is	not	100%	and	several	other	important	biomarkers	of	response	are	likely	to	exist.	•	Defects	in	antigen	processing	and	presentation:	This	includes	downregulation	of	MHC	class	I	on	tumour	cells	is	also	a	common	mechanism	by	which	tumours	avoid	CD8+	T	cell	recognition	(Reeves	&	James,	2017).				 	
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Box	2:	DNA	damaging	compounds	in	clinical	use	or	development.		 Drug	class	 Predominant	mechanism	of	action	 Examples	
D
N
A	
da
m
ag
in
g	
ag
en
ts
	
Alkylating	agents	 Alkyl	attachment	to	DNA	 Bendamustine	Cyclophosphamide	Melphalan,	Ifosfamide		Anthracyclines	 Intercalate	DNA	 Doxorubicin	Epirubicin	Antimetabolites	 Cytidine	analogue/ribonucleotide	reductase	inhibitor	Thymidylate	synthase	(TS)	inhibitor	Dihydrofolate	reductase	(DFS)	inhibitor	Inhibits	TS,	DFS	and	glycinamide	ribonucleotide	formyltransferase	
Gemcitabine		5-FU/Capecitabine	Methotrexate	Pemetrexed	Anti-mitotics	 Stabilise	microtubules	Inhibit	microtubule	polymerisation	 Docetaxel,	Paclitaxel	Vinorelbine	Platinum	based	 Inter-	and	intra-strand	DNA	cross	links	 Cisplatin,	Carboplatin,	Oxaliplatin	Radiomimetics	 Reactive	oxygen	species	damage	 Bleomycin	Topoisomerase	I	inhibitor	 Trap	topoisomerase	I	 Etoposide	Topoisomerase	II	inhibitor	 Trap	topoisomerase	II	 Irinotecan,	Topotecan	
D
N
A	
re
pa
ir
	
in
hi
bi
to
rs
	
ATM	inhibitors	 Inhibits	G1-S	and	intra-S	checkpoint	activation,	impairing	global	DSB	repair	 AZD0156	ATR	inhibitors	 Inhibits	G2-M	and	intra-S	checkpoint	activation,	impairing	DNA	replication	associated	DSB	repair	 VX-970,	AZD6738	CHK1	inhibitors	 Inhibits	G2-M	and	intra-S	checkpoint	activation,	impairing	DNA	replication	associated	DSB	repair	 MK8776,	LY2603618	DNA-PK	inhibitors	 Inhibit	DSB	repair	by	non-homologous	recombination	 MSC2490484A,	VX-984		PARP	inhibitors	 Trap	PARP	on	DNA	and	inhibit	single	stranded	DNA	break	repair	 Olaparib,	Rucaparib,	Niraparib,	Talazoparib,	Veliparib	WEE1	inhibitor	 CDK1/2	inhibitor	 AZD1775		
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Ip
ili
m
um
ab Melanoma
N
iv
ol
um
ab
Melanoma
Urothelial
Regulatory	approvalLine	of	
treatmentTumor	group Trial	name
2nd Keynote	045 May-17 NA NA PMID:	28212060MSI-H/dMMR	Solid	Tumour 2nd NA May-17 NA NA2nd NA May-16 Jul-17 NA PMID:	26952546	1st		(platinum	ineligible) IMvigor210 Apr-17 Jul-17 NALung 2nd OAK Oct-16 Jul-17 NA PMID:	27979383Urothelial 2nd Study	1108 May-17 NA NA PMID:27269937
D
ur
va
lu
m
ab PDL1
Urothelial
At
ez
ol
iz
um
ab
PD1
Pe
m
br
ol
iz
um
ab
Urothelial

ICI Tumor	group Target	population DDR	agent phase arms Planned	n Trial	status NCT citation/remarks
Breast 3rd	line
Gastric 2nd	line
Ovarian Platinum	sensitive
SCLC 2nd	line
NSCLC/	SCLC 2nd	or	higher	line Durvalumab	+	Olaparib
Breast TNBC,	<	3	prior	lines Durvalumab	+	Cediranib
Ovarian platinum	resistant Durvalumab	+	Olaparib	+	Cediranib
Colorectal 3rd	line
Prostate mCRPC
Ovary gBRCA Olaparib 1/2 Olaparib	+	Durvalumab	+	Tremelimumab 39 Not	yet	recruiting NCT02953457
NSCLC
HNSCC
Tremelimumab Ovarian 2nd	line	+ Olaparib 1/2 Tremelimumab	+	Olaparib 50 recruiting NCT02571725 gBRCA	only
Breast up	to	3	prior	lines TNBC	only
Ovarian up	to	4	prior	lines Platinum	resistant/refractory	only
Veliparib	+	nivolumab	+	platinum	doublet	chemotherapy
Veliparib	+	platinum	doublet	chemotherapy
Adv	solid	tumors refractory	to	std	therapy Veliparib 1 Veliparib	+	Nivolumab 50 Not	yet	recruiting NCT03061188
Veliparib
Atezolizumab
veliparib	+	atezolizumab
BGB-A317 Adv	solid	tumors 2nd	line	+ BGB-290	 1 BGB-A317	+	BGB-290 124 recruiting NCT02660034
Olaparib 1/2Durvalumab 338 recruiting
Olaparib 1/2 Olaparib	+	Durvalumab 133 recruiting
NCT02944396
114
NCT02484404
Pembrolizumab Niraparib 1/2 niraparib	+	pembrolizumab
AZD6738	+	Durvalumabrefractory AZD6738 1 114 recruiting NCT02264678 Has	other	arms	involving	AZD	6738	with	other	agents
1st	line	metastatic Carboplatin	+	paclitaxel	or	pemetrexed	+	Veliparib 2 184 Recruiting
NCT02734004
NA
Atezolizumab Breast Veliparib 2 90 recruiting NCT02849496 TNBC	+	gBRCA	only
Nivolumab
any	prior	therapy	allowed
recruiting NCT02657889
NSCLC
APC
PD-L1
PD-L1
PD-1
effector 
T cells
MDSC
PD-L1
regulatory   
     T cells
CTLA4
tumor cells
immunogenic cell death
inhibit T regs
inhibit MDSCs
expand neoantigen repertoire
modes of action for the direct and indirect immune effects of DNA damaging agents 
neoantigens
activate dendritic cells
increase MHC expression
DIRECTLY INCREASING ANTIGENICITY
                  OF TUMOUR
INDIRECTLY LIFTING IMMUNOSUPPRESSION increasing cross-presentation
                of antigens
MHC class 1
TCR
cystotolic DNA
STING activation
b) FUTURE - IMMUNE BIOMARKER DRIVEN
Patient profiling
Tumour profiling
Host immune response profiling
germline analysis
histopathology
IHC
molecular profiling
PD-L1 expression in tumour/stroma
inflammed OR desert phenotype
cytokine profiling
INFLAMMED TUMOURS
ICI
IMMUNE DESERT TUMOURS
ICI
DD agent
ICI
DD agent
OR
AND
ICI
DD agent
add DD agent at progression
a) CURRENT SCENARIO - DD agent + Immune CheckPoint Combinations trials
Durvalumab 
 +DD agent
Nivolumab 
 +DD agent
Pembrolizumab 
 +DD agent
Atezolizumab
 +DD agent
Brain
Neuroblastoma
HNSCC
NSCLC
SCLC
Mesothelioma
Pancreas
Gastric/Oesophageal
Biliary
Colorectal
Endometrial
 Cervix
Ovary
Bladder
Melanoma
 AML
Hodgkin’s
NHL
Sarcoma
Breast
PD-L1
high lymphocytic infiltration
high PD-L1 expression
minimal lymphocytic infiltration
low PD-L1 expression
